Polarean Imaging PLC New System Installation (3594Z)
18 Septiembre 2020 - 1:00AM
UK Regulatory
TIDMPOLX
RNS Number : 3594Z
Polarean Imaging PLC
18 September 2020
Polarean Imaging Plc
("Polarean" or the "Company")
New System Installation
Polarean Imaging plc (AIM: POLX), the medical-imaging technology
company, with a proprietary investigational drug-device combination
diagnostic for magnetic resonance imaging (MRI), announces that it
has completed the installation of its latest research unit order
for a 9820 Xenon Polariser system at the University of Kansas
Medical Center ("KU Medical Center") http://www.kumc.edu/ .
KU Medical Center is a major research and teaching hospital and
this polariser will form the cornerstone of a new hyperpolarised
129Xe imaging research programme. Following this installation, the
total number of the Company's polarisers installed is 23.
Mario Castro MD MPH Division Chief, Pulmonary, Critical Care and
Sleep Medicine; Vice Chair for Clinical and Translational Research,
Director of the Rainbow Clinical Trials Science Unit, Frontiers of
KU Medical Center said : "We are excited to utilise the latest
technology in lung imaging, hyperpolarised Xenon gas MRI, to
evaluate and assess response to therapy in our patients with lung
disease."
Richard Hullihen, CEO of Polarean, said: "We look forward to
extending our working relationship with KU Medical Center as they
launch their pulmonary research programmes, thereby expanding the
clinical and public health frontiers of hyperpolarised xenon
imaging to help clinicians and patients with lung diseases."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Via Walbrook PR
Officer
Jonathan Allis, Chairman
SP Angel Corporate Finance LLP Nomad Tel: +44 (0)20 3470 0470
and Broker
David Hignell / Soltan Tagiev (Corporate
Finance)
Vadim Alexandre / Rob Rees (Corporate
Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7876
741 001
About Polarean ( www.polarean.com )
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue generating, medical drug-device
combination companies operating in the high resolution medical
imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation and gas exchange regionally
in the smallest airways of the lungs, the tissue barrier between
the lung and the bloodstream and in the pulmonary vasculature.
Xenon gas exhibits solubility and signal properties that enable it
to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need
and the Group's technology provides a novel diagnostic approach,
offering a non-invasive and radiation-free functional imaging
platform which is more accurate and less harmful to the patient
than current methods. The annual burden of pulmonary disease in the
US is estimated to be over US$150 billion.
The Group also develops high performance MRI radiofrequency (RF)
coils which are a required component for imaging (129) Xe in the
MRI system. The development of these coils by the Group facilitates
the adoption of the Xenon technology by providing
application-specific RF coils which optimise the imaging of (129)
Xe in MRI equipment for use as a medical diagnostic as well as a
method of monitoring the efficacy of therapeutic intervention.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDFLFERAIIDLII
(END) Dow Jones Newswires
September 18, 2020 02:00 ET (06:00 GMT)
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024